Skip to main content
Perspective:
Perspective
09 Apr 2024

Unlocking pharma supply chain expertise: how Deloitte can contribute to improve your efficiency and innovation

Coping with supply chain disruptions, has recently become one of the biggest challenge in pharmaceutical and biotechnology industry.

With this set of articles, Deloitte is eager to share a snapshot of its knowledge and capabilities around the topic, with a particular focus on:

  • What is Bionic Demand Planning and why it can be considered the future of demand planning
  • How Deloitte places itself as a catalyst for RNA supply chains, accelerating commercialisation of RNA Therapeutics and Vaccines
  • How Deloitte operates in Pharma and Biotech Supply Chains, reshaping the traditional consulting approach”
Skip to description

Get in touch

Marcus Kutzner

Marcus Kutzner

Partner
+41 58 279 9056

Did you find this useful?

Yes
No

Thanks for your feedback

Your feedback is important to us

To tell us what you think, please update your settings to accept analytics and performance cookies.

Need help updating cookies?

Our thinking

Commercial Operations in Life Sciences

Digital transformation of commercial operations has transitioned from a “nice-to-have” enabler to a “must-have” capability, making it critical for Life Science companies to evaluate how digital tools will deliver customer centricity and service innovation (collectively termed Commercial Excellence) across the commercial operations value chain.
Perspective

Accelerating commercialisation of RNA Therapeutics and Vaccines

Deloitte has successfully supported Biotech companies in scaling up fast and overcoming operational challenges in the mRNA field. In the successful deployment of mRNA vaccines against COVID-19 Deloitte's team of experts acted as catalysts to ensure high speed in the supply chain operations. Learn how Deloitte can help your company thrive in the mRNA value chain.
Perspective

Reinventing Pharma Supply Chain Consulting

In recent years pharmaceutical companies have managed to enter unexplored markets where success is driven by the capability to scale up fast. Profits generated by in demand breakthrough products come often create operational challenges for supply chains.
Perspective

Accelerating to the Future of Customer Engagement

Accelerating to the Future of Customer Engagement
Perspective
Explore our thinking

Let's connect

Deloitte AG is a shareholder in Deloitte EMEA BV (EMEA), which is a member firm of Deloitte Touche Tohmatsu Limited (DTTL). Deloitte EMEA and DTTL do not provide services to clients. Services may be provided by the EMEA shareholders or their affiliates, which are separate and independent legal entities. Please see www.deloitte.com/ch/about to learn more about our global network of member firms.

This communication contains general information only, and none of Deloitte EMEA (EMEA), its shareholders and affiliates is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties, or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of EMEA, the EMEA shareholders, their respective affiliates, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. EMEA, the EMEA shareholders and their respective affiliates are legally separate and independent entities.

Deloitte AG is an audit firm recognised and supervised by the Federal Audit Oversight Authority (FAOA) and the Swiss Financial Market Supervisory Authority (FINMA).

© 2026  For information, contact Deloitte AG.